[CH3:1][N:2](C(CN)=O)[C@@H:3]1[C@@H:8]([O:9][CH3:10])[C@@H:7]([OH:11])[C@H:6]([NH2:12])[C@@H:5]([O:13][C@H:14]2[O:19][C@H:18]([CH2:20][NH2:21])[CH2:17][CH2:16][C@H:15]2[NH2:22])[C@@H:4]1[OH:23].[OH-].[Na+].[OH-].[Ba+2].[OH-].C(=O)=O>>[CH3:1][NH:2][C@@H:3]1[C@@H:8]([O:9][CH3:10])[C@@H:7]([OH:11])[C@H:6]([NH2:12])[C@@H:5]([O:13][C@H:14]2[O:19][C@H:18]([CH2:20][NH2:21])[CH2:17][CH2:16][C@H:15]2[NH2:22])[C@@H:4]1[OH:23]Fortimicin KE may also be obtained by heating Fortimicin D in an alkaline aqueous solution such as sodium hydroxide and barium hydroxide. Specifically, Fortimicin D is heated in an aqueous solution of saturated barium hydroxide at a temperature of 100° C. for 3 hours. Then the reaction solution is neutralized with dry ice and the resulting precipitate of barium carbonate is removed by filtration. The filtrate is concentrated and passed through a column packed with Amberlite CG-50 (ammonium form). After washing the column with water, elution is carried out with 0.2N aqueous ammonia. First, a small amount of reaction by-products is eluted and subsequently Fortimicin KE is eluted. The fractions containing Fortimicin KE are combined and concentrated under reduced pressure. The concentrate is then freeze-dried to obtain the free base of Fortimicin KE.
読み込み中…